Zimmer Biomet Holdings Inc (NYSE:ZBH) finished Friday with a subtraction of -$0.24 to close at $112.22, a downside of -0.21 percent. An average of 2,308,880 shares of common stock have been traded in the last five days. There was a fall of -$4.63 in the past week, and it reached a new high 23 times over the past 12 months. The last 20 days have seen an average of 1,725,470 shares traded, while the 50-day average volume stands at 1,706,382.
ZBH stock has decreased by -6.67% in the last month. The company shares reached their 1-month lowest point of $108.52 on 09/27/23. With the stock rallying to its 52-week high on 05/02/23, shares of the company touched a low of $102.60 and a high of $149.25 in 52 weeks. It has reached a new high 10 times so far this year and lost -11.98% or -$15.28 in price. In spite of this, the price is down -24.81% from the 52-week high.
Insider Transactions
ZBH stock investors should be aware that Zimmer Biomet Holdings Inc (ZBH) stock had its last reported insider trading activity 197 days ago on Aug 30. In this transaction, the insider spent $2,869,113. 10% Owner, ZIMMER BIOMET HOLDINGS, INC., disposed of 5,131,946 shares at a price of $9.57 on Feb 01. The insider now owns more than $49,094,761 worth of shares. Prior to that, Sr. VP/Gen Counsel/Secretary Phipps Chad F went on to Sale 11,522 shares at $128.63 each on Dec 13. An amount of $1,482,079 was transacted.
Valuation Metrics
Zimmer Biomet Holdings Inc (ZBH) has a trailing price-to-earnings (P/E) ratio of 46.68. The stock’s beta is 1.04. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.26, the price-to-book (PB) ratio at 1.89, and the price-to-cash flow ratio at 29.68.
The company has a payout ratio of 87.25%. The company’s most recent quarterly dividend payment was $0.24 a share, without any change from last year. Its latest increase dividend $0.02 reported on Wednesday February 24 2016.
Financial Health
The quick ratio of Zimmer Biomet Holdings Inc for the three months ended June 29 was 0.95, and the current ratio was 1.96, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.42 and a total debt to equity ratio of 0.46 for the quarter ending June 29. Its gross profit as reported stood at $4.92 billion compared to revenue of $6.94 billion.
Earnings Surprise
For the three-month period that ended June 29, Zimmer Biomet Holdings Inc had $5.19 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $209.6 million in the quarter, while revenues of $232.5 million were grew 26.67%. The analyst consensus anticipated Zimmer Biomet Holdings Inc’s latest quarter earnings to come in at $1.81 per share, but it turned out to be $1.82, a 0.60% surprise. For the quarter, EBITDA amounted to $567.2 million. Shareholders own equity worth $208.96 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Zimmer Biomet Holdings Inc (ZBH) price momentum. RSI 9-day as of the close on 29 September was 29.71%, suggesting the stock is oversold, with historical volatility in this time frame at 23.36%.
As of today, ZBH’s price is $113.05 -3.96% or -$4.63 from its 5-day moving average. ZBH is currently trading -5.79% lower than its 20-day SMA and -18.35% lower than its 100-day SMA. However, the stock’s current price level is -21.38% below the SMA50 and -11.03% below the SMA200.
The stochastic %K and %D were 22.37% and 15.31%, respectively, and the average true range (ATR) was 2.65. With the 14-day stochastic at 25.43% and the average true range at 2.56, the RSI (14) stands at 32.30%. The stock has reached -3.94 on the 9-day MACD Oscillator while the 14-day reading was at -5.96.
Analyst Ratings
BTIG Research upgraded Zimmer Biomet Holdings Inc (NYSE: ZBH) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Zimmer Biomet Holdings Inc (ZBH) among analysts is Hold. According to current brokerage recommendations, 2 brokerage firms advise that investors sell ZBH, while 14 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 8 others rate it as a “buy”.
What is ZBH’s price target for the next 12 months?
Analysts predict a range of price targets between $120.00 and $172.00, with a median target of $150.25. Taking a look at these predictions, the average price target given by analysts for Zimmer Biomet Holdings Inc (ZBH) stock is $149.98.
